{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:36:14Z","timestamp":1785105374229,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>For a cohort of prostate cancer patients treated on an MR-guided radiotherapy (MRgRT) system, we retrospectively analyzed urethral interfractional geometric and dosimetric variations based on onboard MRIs acquired at different timepoints and evaluated onboard prostatic urethra visualization for urethra-focused online adaptive RT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-six prostate cancer patients were prospectively scanned on a 0.35-T MRgRT system using an optimized T2-weighted HASTE sequence at simulation and final fraction. Two radiation oncologists (RO1 and RO2) contoured the urethras on all HASTE images. The simulation and final fraction HASTE images were rigidly registered, and urethral interobserver and interfractional geometric variation was evaluated using the 95th percentile Hausdorff distance (HD95), mean distance to agreement (MDA), center-of-mass shift (COMS), and DICE coefficient. For dosimetric analysis, simulation and final fraction HASTE images were registered to the 3D bSSFP planning MRI and 3D bSSFP final setup MRI, respectively. Both ROs\u2019 urethra contours were transferred from HASTE images for initial treatment plan optimization and final fraction dose estimation separately. Stereotactic body radiotherapy (SBRT) plans, 40\u00a0Gy in 5 fractions, were optimized to meet clinical constraints, including urethral V42Gy \u22640.03\u00a0cc, on the planning MRI. The initial plan was then forward calculated on the final setup MRI to estimate urethral dose on the final fraction and evaluate urethral dosimetric impact due to anatomy change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The average interobserver HD95, MDA, COMS, and DICE were 2.85\u00a0\u00b1\u00a01.34\u00a0mm, 1.02\u00a0\u00b1\u00a00.36\u00a0mm, 3.16\u00a0\u00b1\u00a01.61\u00a0mm, and 0.58\u00a0\u00b1\u00a00.15, respectively. The average interfractional HD95, MDA, COMS, and DICE were 3.26\u00a0\u00b1\u00a01.54\u00a0mm, 1.29\u00a0\u00b1\u00a00.54\u00a0mm, 3.34\u00a0\u00b1\u00a02.01\u00a0mm, and 0.49\u00a0\u00b1\u00a00.18, respectively. All patient simulation MRgRT plans met all clinical constraints. For RO1 and RO2, 23\/26 (88%) and 21\/26 (81%) patients\u2019 final fraction estimated urethral dose did not meet the planned constraint. The average urethral V42Gy change was 0.48\u00a0\u00b1\u00a00.58\u00a0cc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Urethral interfractional motion and anatomic change can result in daily treatment violating urethral constraints. Onboard MRI with good visualization of the prostatic urethra can be a valuable tool to help better protect the urethra through patient setup or online adaptive RT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.916254","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:25:39Z","timestamp":1657862739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Urethral Interfractional Geometric and Dosimetric Variations of Prostate Cancer Patients: A Study Using an Onboard MRI"],"prefix":"10.3389","volume":"12","author":[{"given":"Jonathan","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky R.","family":"Savjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar\u00a0U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/JNCCN.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/JAMANETWORKOPEN.2018.8006","article-title":"Long-Term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8\/ATTACHMENT\/F9776432-045B-4658-9ED8-001722D244A2\/MMC1.PDF","article-title":"Intensity-Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings From an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6\/ATTACHMENT\/BE42A27F-79B9-4D7D-93AE-F4FF9FDFE327\/MMC1.PDF","article-title":"Ultra-Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-021-08281-X","article-title":"Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (Mirage): A Phase Iii Randomized Trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2006.10.042","article-title":"Investigation of Bladder Dose and Volume Factors Influencing Late Urinary Toxicity After External Beam Radiotherapy for Prostate Cancer","volume":"67","author":"Cheung","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2020.09.054\/ATTACHMENT\/3115C618-1565-42D0-9072-4BE340E8138D\/MMC1.DOCX","article-title":"Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.IJROBP.2021.06.037","article-title":"Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.2966","article-title":"Once-A-Week or Every-Other-Day Urethra-Sparing Prostate Cancer Stereotactic Body Radiotherapy, a Randomized Phase II Trial: 18 Months Follow-Up Results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancerdresults From a Multi-Institutional Clinical Trial *","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2017.08.005","article-title":"Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens","volume":"73","author":"Takeda","year":"2018","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1118\/1.598912","article-title":"Determination of the Urethral Dose in Prostate Brachytherapy When the Urethra Cannot Be Visualized in the Postimplant CT Scan","volume":"27","author":"Waterman","year":"2000","journal-title":"Med Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mp.12830","article-title":"Changes in Prostate Orientation Due to Removal of a Foley Catheter","volume":"45","author":"Litzenberg","year":"2018","journal-title":"Med Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1424-8","article-title":"The Urethral Position may Shift Due to Urethral Catheter Placement in the Treatment Planning for Prostate Radiation Therapy","volume":"14","author":"Dekura","year":"2019","journal-title":"Radiat Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1259\/BJR.20160348","article-title":"Simple Diagrammatic Method to Delineate Male Urethra in Prostate Cancer Radiotherapy: An MRI Based Approach","volume":"89","author":"Kataria","year":"2016","journal-title":"Br J Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRRO.2019.06.009","article-title":"Comparison of Motion-Insensitive T2-Weighted MRI Pulse Sequences for Visualization of the Prostatic Urethra During MR Simulation","volume":"9","author":"Zakian","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/JMRS.485","article-title":"Visualising the Urethra for Prostate Radiotherapy Planning","volume":"68","author":"Richardson","year":"2021","journal-title":"J Med Radiat Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2016.2581881","article-title":"MRI to CT Prostate Registration for Improved Targeting in Cancer External Beam Radiotherapy","volume":"21","author":"Commandeur","year":"2017","journal-title":"IEEE J BioMed Heal Inf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ACM2.12529","article-title":"Improving Fiducial and Prostate Capsule Visualization for Radiotherapy Planning Using MRI","volume":"20","author":"Pathmanathan","year":"2019","journal-title":"J Appl Clin Med Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1821090","article-title":"Daily Dosimetric Variation Between Image-Guided Volumetric Modulated Arc Radiotherapy and MR-Guided Daily Adaptive Radiotherapy for Prostate Cancer Stereotactic Body Radiotherapy","volume":"60","author":"Nicosia","year":"2021","journal-title":"Acta Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.616291\/BIBTEX","article-title":"MR-Guided Radiotherapy for Prostate Cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13143564","article-title":"Evaluation of T2-Weighted Mri for Visualization and Sparing of Urethra With Mr-Guided Radiation Therapy (Mrgrt) on-Board Mri","volume":"13","author":"Pham","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.RADONC.2021.12.037","article-title":"Dosimetric Impact of Interfraction Prostate and Seminal Vesicle Volume Changes and Rotation: A Post-Hoc Analysis of a Phase III Randomized Trial of MRI-Guided Versus CT-Guided Stereotactic Body Radiotherapy","volume":"167","author":"Ma","year":"2022","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.916254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:25:41Z","timestamp":1657862741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.916254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":23,"alternative-id":["10.3389\/fonc.2022.916254"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.916254","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"article-number":"916254"}}